Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: A pilot study

Melanoma Research

Volumn 13, Issue 1, 2003, Pages 51-58

  Guadagni, Stefano ^a   Santinami, Mario ^b   Patuzzo, Roberto ^b   Pilati, Pier Luigi ^c   Miotto, Diego ^c   Deraco, Marcello ^b   Rossi, Carlo Riccardo ^c   Fiorentini, Giammaria ^d   Di Filippo, Franco ^e   Valenti, Marco ^a   Amicucci, Gianfranco ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Department of Oncology   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hypoxia; Locoregional chemotherapy; Melanoma; Melphalan; Mitomycin C; Perfusion; Stop flow

Indexed keywords

MELPHALAN; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOFILTRATION; HUMAN; HYPOXIA; LIMB PERFUSION; LUNG EMBOLISM; MALE; MELANOMA; NAUSEA; NEUTROPENIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE PROGRESSION; EXTREMITIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MELPHALAN; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0037331366     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200302000-00009     Document Type: Article

References (32)

1. Cavaliere R, Di Filippo F, Giannarelli D. Hyperthermic antiblastic perfusion in the treatment of local recurrence or in transit metastases of limb melanoma. Semin Surg Oncol 1992; 8:374-380.
2. Vrouenraets BC, Hart CA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999; 188:522-530.
3. Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7:188-192.
4. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41:73-81.
5. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 1986; 38:229-235.
6. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997; 39:541-546.
7. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MC, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80:161-166.
8. Fiorentini G, Poddie D, Graziani G, Ricci S, Baccini C, Rossi G, et al. Hypoxic isolated limb perfusion with mitomycin C in locally recurrent melanoma and sarcoma: result of a phase II study. Reg Cancer Treat 1995; 8:135-139.
9. Thompson JF, Kam PCA, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14:238-247.
10. Aigner KR, Kaevel K. Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat 1994; 7:6-11.
11. Kroon BBR. Regional isolated perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 1992; 14:101-110.
12. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of new staging system. J Clin Oncol 1997; 15:1039-1051
13. Smith JL. Histopathology and biologic behavior of malignant melanoma. In: Neoplasms of the Skin and Malignant Melanoma. Chicago: Year Book Medical Publishers; 1976, pp. 293-330.
14. Wieberdink J, Benckhuijsen C, Braat RP, Van Slooten EA, Olthius GAA. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.
15. Sonneveld EJ, Vrouenraets BC, van Geel BN, Eggermont AM, Klaase JM, Nieweg OE, et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996; 22:521-527.
16. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491-502.
17. Klicks RJ, Vrouenraets BC, Nieweg OE, Kroon BB. Vascular complications of isolated limb perfusion. Eur J Surg Oncol 1998; 24:288-291.
18. Vrouenraets BC, Eggermont AM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, et al. Regional toxicity after isolated limb perfusion with melphalan and tumor necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 21:390-395.
19. Vrouenraets BC, in't Veld GJ, Nieweg OE, van Slooten GW, van Dongen JA, Kroon BB. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999; 25:503-508.
20. Vrouenraets BC, Eggermont AM, Klaase JM, van Geel BN, van Dongen JA, Kroon BB. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 1994; 20:681-685.
21. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 2001; 44:189-192.
22. Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001; 11:423-431.
23. Ross WE, Ewig RA, Kohn KW. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res 1978; 38:1502-1506.
24. Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 1999; 80:1223-1230.
25. Thompson JF, Liu M, Waugh RC, Watson LD, Sheldon DM, Stephen MS, et al. A percutaneous aortic 'stop-flow' infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994; 7:202-207.
26. Guadagni S, Russo F, Rossi CR, Pilati PL, Miotto D, Fiorentini G, et al. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg 2002; 183:28-36.
27. Hoekstra HJ, Naujocks T, Schraffordt Koops H, Beekhuis H, van Groningen a Stuling R, et al. Continous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg Cancer Treat 1992; 4:301-304.
28. Cavaliere R, Ciocatto RC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967; 20:1351-1381.
29. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon-alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1762-1769.
30. McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon-alfa-2B in patients with metastatic melanoma. Clin Cancer Res 2000; 6:2201-2208.
31. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, et al. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs 1999; 10:735-739.
32. Wile A, Smolin M. Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer. Arch Surg 1987; 122:1321-1325.